Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.49 |
| ▸ | GDA | Q9Y2T3 | 3/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 6/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10997 | 0.74 | MAPT (0.53) | MAPTADORA2BGDAACHEALDH1A1 | |
| Uric Acid SCHEMBL28407297 | 0.74 | MAPT (0.53) | MAPTADORA2BGDAACHEALDH1A1 | |
| SCHEMBL30728071 | 0.74 | MAPT (0.53) | MAPTADORA2BGDAACHEALDH1A1 | |
| Uric Acid SCHEMBL30269772 | 0.74 | MAPT (0.53) | MAPTADORA2BGDAACHEALDH1A1 | |
| SCHEMBL30537976 | 0.74 | ALDH1A1 (0.60) | MAPTADORA2BGDAACHEALDH1A1 | |
| SCHEMBL932609 | 0.74 | MAPT (0.53) | MAPTADORA2BGDAACHEALDH1A1 | |
| SCHEMBL29737686 | 0.74 | MAPT (0.53) | MAPTADORA2BGDAACHEALDH1A1 | |
| SCHEMBL932949 | 0.74 | MAPT (0.53) | MAPTADORA2BGDAACHEALDH1A1 | |
| Uric Acid SCHEMBL2786719 | 0.74 | MAPT (0.53) | MAPTADORA2BGDAACHEALDH1A1 | |
| SCHEMBL2837685 | 0.74 | MAPT (0.53) | MAPTADORA2BGDAACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012178101-A2 | COMPOSITIONS AND METHODS TO REMOVE GENETIC MARKERS USING COUNTER-SELECTION | JOULE UNLIMITED TECHNOLOGIES, INC. (US) | 2012-12-27 | — | — | WO | claimed |
| JP-2160720-A | — | — | None | — | — | JP | disclosed |
| EP-2430036-B1 | SUBSTITUTED 6-(BENZYLAMINO) PURINE RIBOSIDE DERIVATIVES, USE THEREOF AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2014-07-30 | — | — | EP | disclosed |
| US-20140066394-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | BIOPATTERNS, S.R.O (CZ) | 2014-03-06 | — | — | US | disclosed |
| EP-2173173-B1 | SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIV PALACKEHO (CZ) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012178101-A2 | COMPOSITIONS AND METHODS TO REMOVE GENETIC MARKERS USING COUNTER-SELECTION | JOULE UNLIMITED TECHNOLOGIES, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-8222260-B2 | Substituted 6-anilinopurine derivatives as inhibitors of cytokinin oxidase/dehydrogenase and preparations containing these derivatives | Univerzita Palackego V Olomouci (CZ) | 2012-07-17 | — | — | US | disclosed |
| US-20120071433-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2012-03-22 | — | — | US | disclosed |
| EP-2430036-A1 | SUBSTITUTED 6-(BENZYLAMINO) PURINE RIBOSIDE DERIVATIVES, USE THEREOF AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130233-A1 | SUBSTITUTED 6-(BENZYLAMINO) PURINE RIBOSIDE DERIVATIVES, USE THEREOF AND COMPOSITIONS CONTAINING THESE DERIVATIVES | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2010-11-18 | — | — | WO | disclosed |
| EP-0903981-A4 | DESIGN OF NOVEL HIGHLY EFFICIENT HIV BASED PACKAGING SYSTEMS FOR GENE THERAPY | UNIV CALIFORNIA (US) | 2002-07-17 | — | — | EP | disclosed |
| CN-1343260-A | Electropolymerizable film, and method of making and use thereof | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2002-04-03 | — | — | CN | disclosed |
| US-20020028823-A1 | THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALING AND METHODS FOR USING SAME | CELL THERAPEUTICS, INC. | 2002-03-07 | — | — | US | disclosed |
| EP-1171442-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2002-01-16 | — | — | EP | disclosed |
| US-6323019-B1 | EXPRESSION VECTORS; FOR USE IN THE TREATMENT OF VIRAL DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-11-27 | — | — | US | disclosed |
| US-6200811-B1 | FOR MAKING HUMAN IMMUNODEFICIENCY VIRUS RESISTANT CELLS; GENE THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-03-13 | — | — | US | disclosed |
| WO-2000061583-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| EP-0903981-A1 | DESIGN OF NOVEL HIGHLY EFFICIENT HIV BASED PACKAGING SYSTEMS FOR GENE THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-03-31 | — | — | EP | disclosed |
| WO-1997036481-A1 | DESIGN OF NOVEL HIGHLY EFFICIENT HIV BASED PACKAGING SYSTEMS FOR GENE THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-10-09 | — | — | WO | disclosed |
| JP-H02160720-A | PHARMACEUTICAL COMPOSITION | BEECHAM WUELFING GMBH & CO KG | 1990-06-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066394-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | PNP, NUDT1, TYMP | MAPT 4552/4885ADORA2B 294/4885GDA 206/4885 |
| US-20120071433-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | CD38, NUDT1, PNP | MAPT 4262/4885ADORA2B 161/4885GDA 217/4885 |
| US-20020028823-A1 | THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALING AND METHODS FOR USING SAME | CCR10, IL1RN, CCR1 | MAPT 2388/4885ADORA2B 1938/4885GDA 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.